• / Free eNewsletters & Magazine
  • / My Account

CVS

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. CVS Caremark CVS Q1 2014 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by. Welcome to the CVS Caremark Q1 2014 Earnings Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. As a reminder, this conference is being recorded Friday, ...

  2. UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

    UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

  3. UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

    UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

  4. UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

    UPDATE: CVS takes on Mylan's EpiPen with much cheaper version of an alternative

  5. CVS to offer low-cost version of EpiPen generic priced at $109.99 for a two-pack

    CVS to offer low-cost version of EpiPen generic priced at $109.99 for a two-pack

  6. Walgreens Boots CEO: No Plan B for Rite Aid Merger--Update

    Walgreens Boots CEO: No Plan B for Rite Aid Merger--Update

  7. Blink Health Announces Arbor Patient Access Program

    Blink Health Announces Arbor Patient Access Program

  8. CVS ’s Ban? Big Tobacco Shrugs

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  9. PBMs: Health Care's Hidden Gems

    Pharmacy benefit managers aren't household names, but recent consolidation in the industry is proving out the power of scale for these firms, says Morningstar's Matt Coffina.

  10. 10 for ’14

    On Sunday, Caremark RX CMX announced that its board unanimously rejected Express Scripts' ESRX bid for the company and will continue to pursue the merger with CVS CVS . We are not changing our fair value estimates as a result of this announcement, since our estimates for all firms assume that CVS ...

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.